Filing Details
- Accession Number:
- 0001209191-22-048900
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-09-06 19:54:16
- Reporting Period:
- 2022-09-01
- Accepted Time:
- 2022-09-06 19:54:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1845337 | Day One Biopharmaceuticals Inc. | DAWN | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1655962 | Ii N Charles York | 395 Oyster Point Blvd, Suite 217 South San Francisco CA 94080 | Coo, Cfo And Secretary | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2022-09-01 | 8,606 | $23.16 | 315,795 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-09-01 | 1,394 | $23.80 | 314,401 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 15, 2021.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.7100 to $23.6800 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.7100 to $23.8500 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Billionaire Hedge Funds
